Abstract:Cancer remains a major global cause of death, posing significant treatment challenges. The interactions between tumor cells and the tumor microenvironment (TME) are crucial in influencing tumor initiation, progression, metastasis, and treatment response. There has been significant research and clinical interest in targeting the TME as a therapeutic approach in cancer, with advancements being made through drug development. Histamine binds to HRH1 receptors on the TME, which inhibit CD8+ T cell activity, promote tumor growth, and contribute to resistance against immunotherapy. By inhibiting CD8+ T cells, the effectiveness of immunotherapies targeting these cells is reduced. By blocking the HRH1 pathway, H1-antihistamines can mitigate this suppression and enhance the response to immunotherapies that target CD8+ T cells. Therefore, understanding the role of histamine and its potential impact on T cells and the role of H1-antihistamines in improving immune-oncology (I/O) agents' efficacy ultimately could lead to more effective cancer therapies. The objective of this review is to examine the current literature to investigate the potential role of H1-antihistamines on the effectiveness of I/O drugs and their role in enhancing treatment against cancer. We conducted a comprehensive literature search, which included multiple databases including PubMed, Google Scholar, and EMBASE, as well as a search of oncology congresses. Our literature review initially identified thirty studies. Twenty-three of these were excluded for failing to meet inclusion criteria, which varied from study design to the type of antihistamines and patient populations involved. The clinical studies investigated the effect of different generations of H1-antihistamines in combination with I/O treatments on patients' outcomes. The findings from these studies indicated that patients using H1-antihistamines concomitantly with I/O agents experienced longer median overall survival (mOS), progression-free survival (mPFS), or improved survival compared to those who did not use antihistamines. Additionally, these trials differentiated between cationic and non-cationic H1-antihistamines, revealing that users of cationic antihistamines had overall better outcomes in terms of longer mOS and mPFS. The assessed trials were consistent in their comparisons of quantitative and qualitative, efficacy, and safety outcomes. Checkpoint inhibitors represent a significant breakthrough in cancer treatment; however, only 20-40% of patients respond to immunotherapies due to many factors, among them the highly immunosuppressive conditions of the TME in some cancer types. H1-antihistamines have been shown to potentiate the activity of immunotherapy by enhancing T cell activation in the TME. We reviewed the role of H1-antihistamines on clinical activity of immuno-oncology agents and integrated key clinical studies into a comprehensive resource for the first time, offering invaluable insights for future research. Drawing from our extensive experience in immuno-oncology clinical trials, the manuscript also provides practical recommendations for future research and therapeutic strategies to be implemented effectively.

H2 antihistamines: May be useful for combination therapies in cancer?

Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings

Nanotherapeutics for Hydrogen Sulfide-Involved Treatment: an Emerging Approach for Cancer Therapy

Antihistamines for cancer immunotherapy: More than just treating allergies

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Combination of H1 and H2 Histamine Receptor Antagonists: Current Knowledge and Perspectives of a Classic Treatment Strategy

Molecular Hydrogen as a Novel Antitumor Agent: Possible Mechanisms Underlying Gene Expression

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Prospects of molecular hydrogen in cancer prevention and treatment

Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine

Molecular Hydrogen Protects against Various Tissue Injuries from Side Effects of Anticancer Drugs by Reducing Oxidative Stress and Inflammation

2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor

2-Aminobenzothiazoles in anticancer drug design and discovery

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

Targeting the adrenomedullin-2 receptor for the discovery and development of novel anti-cancer agents

Advanced HER2-positive gastric cancer: current and future targeted therapies

Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress

Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Non-anticoagulant heparins and inhibition of cancer